Pipeline Setback at Can-Fite BioPharma, Shares Down

31-12-2013 Zacks.comComments (0)

BiotechnologyCan-Fite BioPharma

Can-Fite BioPharma Ltd. (CANF) suffered a setback when its pipeline candidate CF101 did not fare well in a 24 week phase III placebo controlled study (n=237). The study evaluated patients suffering from moderate-to-severe dry eye syndrome. The news ...

Read more on Zacks.com

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top